Check a real trial opportunity
A trial becomes a real option only when the relevant site and cohort can evaluate the patient under the current protocol. A registry listing is the beginning of that check.
Before you start: Trial phases and randomization explains what a study asks and how it assigns treatment. Clinical trials versus expanded access separates trial participation from treatment outside a study.
Where this step sits
You have named the access route. Here you learn how to move from a promising trial name to specific questions for its team. The last lesson covers readiness after the route is identified.
Read the protocol as a set of gates
The protocol is the study's detailed plan. It defines who may join, what treatment they receive, the monitoring schedule and the outcomes being studied. A public summary can help you decide whether to ask about screening. It does not replace the full eligibility assessment.
Check the disease and treatment setting first. A trial for advanced cancer may require measurable disease. A trial after surgery may require particular pathology and enrollment within a defined interval. The same molecular feature can appear in both studies while the entry rules remain very different.
Then inspect prior treatments, relevant medical conditions, current medicines, laboratory requirements and sample needs. A washout period is a protocol-defined interval after a prior treatment or medication. Do not guess its start date or assume that one study's rule applies to another.
A clinician and study team can distinguish a clear mismatch from a question requiring review. Keep the uncertain items marked uncertain. A self-made eligibility sheet is useful preparation; it is not an enrollment decision.
Ask about the cohort and the site
A study may have several cohorts: groups defined by disease, biomarker, dose or treatment history. The overall study can be recruiting while the cohort of interest is closed. Likewise, one site may be listed but not currently enrolling that cohort.
Use a compact screening record:
| Item | What to confirm |
|---|---|
| Identity | Registry number, trial title and protocol version |
| Scientific fit | Disease, stage, treatment goal and required biomarker |
| Medical fit | Prior therapies, safety history, medicines and laboratory gates |
| Local availability | Relevant cohort, open slot and site readiness |
| Assignment | Study groups, randomization ratio and what each group receives |
| Schedule | Screening, visits, treatment duration and follow-up |
| Practical fit | Travel, sample requirements, support and payment questions |
| Current answer | Who confirmed it, when, and which questions remain open |
Ask for the current protocol or consent materials when available. If a registry and site answer differ, record the difference and ask the study team to clarify it.
Worked example: a fictional randomized study
Mara finds a recruiting study of Drug B after surgery. The public page says it compares Drug B plus standard care with standard care alone. Her molecular report mentions the same pathway as Drug B.
That is enough to ask for a screening conversation, but several questions remain. Does the pathology meet the entry rule? Is the local cohort open? Does her treatment history fit? Can the required visits happen within the permitted time window?
If the trial is randomized, Mara may receive standard care alone. Her doctor cannot simply select Drug B because it sounds more promising. The comparison is part of the research question. She should understand both groups before deciding whether participation fits her goals.
A placebo is an inactive comparison product. Its presence does not necessarily mean withholding standard treatment. Some cancer trials compare standard care plus a placebo with standard care plus the investigational drug. The actual protocol and consent form tell you what each group receives.
What can go wrong at this step
- A target match becomes eligibility. Disease, prior treatment and safety gates still apply.
- Overall recruiting status becomes local availability. Confirm the site and cohort.
- A phase label becomes a personal benefit estimate. The phase identifies study questions, not a guarantee.
- A screening invitation becomes enrollment. Further review or tests may still identify a mismatch.
- A deadline drives an unsupervised treatment change. Review sequencing and washout questions with the treating and study teams.
Try it
A fictional registry lists a multicohort trial as recruiting. The nearest site says the breast-cancer cohort has no open slots. Is access confirmed?
Answer: No. The overall recruiting label does not establish an available slot in that site and cohort. Ask whether another participating site is open, whether the relevant cohort is expected to reopen, and which current eligibility questions need review. Keep these as inquiries rather than promises.
Explain it back
Complete: “The study is recruiting overall, but we still need to confirm ____, ____ and ____.”
One possible answer: “The relevant cohort, an available site or slot, and formal eligibility.”
Takeaway
Carry the protocol, cohort, site and date of confirmation together when calling a trial a possible option.
Next: Build the readiness picture.
Sources and scope
Source check: October 9, 2026. Mara's study is fictional, with no claim of a current opening. Expert and learner review pending.
- NCI: steps to find a clinical trial — eligibility preparation and site contact.
- NCI: how clinical trials work — assignment and controls.
- NCI: what to expect during a clinical trial — pre-screening, consent and screening stages.